William C Cushman
- Achieving blood pressure goals: why aren't we?William C Cushman
University of Tennessee College of Medicine, Memphis, TN 38104, USA
J Clin Hypertens (Greenwich) 8:865-72. 2006....
- Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive AgentsW C Cushman
Department of Veterans Affairs Research and Development Service, Veterans Affairs Medical Center, Memphis, Tenn 38104, USA
Arch Intern Med 160:825-31. 2000..Stroke incidence and mortality rates are higher in the southeastern region of the United States, which is called the "Stroke Belt." We compared the response to antihypertensive medication use in patients from different US regions...
- Pulse pressure changes with six classes of antihypertensive agents in a randomized, controlled trialW C Cushman
Veterans Affairs Medical Center, Memphis, Tennessee, USA
Hypertension 38:953-7. 2001..0 mm Hg) were intermediate. These data show that classes of antihypertensive agents differ in their ability to reduce pulse pressure. Whether these differences affect rates of cardiovascular events remains to be determined...
- Hypertension control in clinical practice with a new standard in angiotensin II receptor blockadeWilliam C Cushman
Veterans Affairs Medical Center, Memphis, Tennessee 38104, USA
Am J Hypertens 15:99S-100S. 2002
- Azilsartan medoxomil plus chlorthalidone reduces blood pressure more effectively than olmesartan plus hydrochlorothiazide in stage 2 systolic hypertensionWilliam C Cushman
University of Tennessee College of Medicine, Memphis, TN, USA
Hypertension 60:310-8. 2012..This large, forced-titration study has demonstrated superior antihypertensive efficacy of azilsartan medoxomil/chlorthalidone fixed-dose combinations compared with the maximum approved dose of olmesartan/hydrochlorothiazide...
- Mortality and morbidity during and after the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialWilliam C Cushman
Memphis Veterans Affairs Medical Center, Memphis, TN, USA
J Clin Hypertens (Greenwich) 14:20-31. 2012..These findings suggest that neither calcium channel blockers nor angiotensin-converting enzyme inhibitors are superior to diuretics for the long-term prevention of major cardiovascular complications of hypertension...
- Blood pressure control by drug group in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)William C Cushman
From the Veterans Affairs Medical Center, Memphis, TN, USA
J Clin Hypertens (Greenwich) 10:751-60. 2008..BP control was achieved in the majority of each randomized group-a greater proportion with chlorthalidone. Over time, providers and patients should expect multidrug therapy to achieve BP <140/90 mm Hg in a majority of patients...
- Home and clinic blood pressure responses in elderly individuals with systolic hypertensionWilliam C Cushman
University of Tennessee and the VA Medical Center, Memphis, TN 38103, USA
J Am Soc Hypertens 6:210-8. 2012..Home BP monitoring, if done with proper technique, provides a reliable indicator of BP control in elderly patients and may help guide drug dosing and titration...
- Rationale and design for the blood pressure intervention of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialWilliam C Cushman
Memphis Veterans Affairs Medical Center, Memphis, Tennessee 38104, USA
Am J Cardiol 99:44i-55i. 2007..The ACCORD blood pressure trial should provide the first definitive clinical trial data on the possible benefit of treating to a more aggressive systolic blood pressure goal in reducing CVD events in patients with diabetes mellitus...
- Are there benefits to specific antihypertensive drug therapy?William C Cushman
University of Tennessee College of Medicine, Memphis, Tennessee 38104, USA
Am J Hypertens 16:31S-35S. 2003..A primary goal in treating hypertension should be to reach a patient's goal BP, but initial selection of drugs based on hypertension morbidity study results and other compelling indications should be given priority...
- Disparity implications of Medicare eligibility criteria for medication therapy management servicesJunling Wang
Department of Pharmaceutical Sciences, University of Tennessee College of Pharmacy, 847 Monroe Avenue, Room 205R, Memphis, TN 38163, USA
Health Serv Res 45:1061-82. 2010..To determine whether there would be racial and ethnic disparities in meeting eligibility criteria for medication therapy management (MTM) services implemented in 2006 for Medicare beneficiaries...
- The effect of a losartan-based treatment regimen on isolated systolic hypertensionWilliam C Cushman
Preventive Medicine Section 111Q, Veterans Affairs Medical Center, 1030 Jefferson Avenue, Memphis, TN 38104, USA
J Clin Hypertens (Greenwich) 4:101-7. 2002..The losartan-based regimen exhibited antihypertensive efficacy that was superior to that of placebo, with a similar tolerability profile...
- JNC-7 guidelines: are they still relevant?William C Cushman
University of Tennessee College of Medicine, Preventive Medicine Section 111Q, Veterans Affairs Medical Center, 1030 Jefferson Ave, Memphis, TN 38104, USA
Curr Hypertens Rep 9:380-6. 2007..Although a new JNC report would be reassuring to practitioners and should include some changes since JNC 7, I consider most of the recommendations to still be relevant today...
- Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in older vs younger patients with hypertension uncontrolled with monotherapyWilliam C Cushman
University of Tennessee College of Medicine and Veterans Affairs Medical Center, Memphis, TN, USA
Am J Geriatr Cardiol 17:27-36. 2008..Irbesartan/HCTZ combination therapy allowed SBP goal attainment in 73% of patients aged 65 years or older whose hypertension was previously uncontrolled with antihypertensive monotherapy...
- The Association Between Antihypertensive Medication Nonadherence and Visit-to-Visit Variability of Blood Pressure: Findings From the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack TrialIan M Kronish
From the Center for Behavioral Cardiovascular Health, Columbia University Medical Center, New York, NY I M K Department of Epidemiology A I L, P M and Division of Cardiology S O, University of Alabama at Birmingham Primary Care Division, Clement J Zablocki VA Medical Center, Milwaukee, WI J W Coordinating Center for Clinical Trials, The University of Texas School of Public Health, Houston B R D, L M S Department of Medicine, Tulane University School of Medicine, Department of Epidemiology, Tulane University School of Public Health, and Tropical Medicine, Research Division, Ochsner Health System M K W Preventive Medicine Section, Veterans Affairs Medical Center, Memphis, TN W C C and Division of Nephrology, Department of Medicine, Stanford University School of Medicine, Palo Alto, CA T I C
Hypertension 68:39-45. 2016..In conclusion, improving medication adherence may lower VVV of BP. However, VVV of BP is associated with cardiovascular outcomes independent of medication adherence. ..
- The burden of uncontrolled hypertension: morbidity and mortality associated with disease progressionWilliam C Cushman
Department of Preventive Medicine, University of Tennessee College of Medicine, Memphis, TN 38104, USA
J Clin Hypertens (Greenwich) 5:14-22. 2003....
- Antihypertensive medication adherence, ambulatory visits, and risk of stroke and deathJames E Bailey
Division of General Internal Medicine, Department of Medicine, University of Tennessee Health Science Center, 956 Court Avenue, Coleman D222, Memphis, TN 38163, USA
J Gen Intern Med 25:495-503. 2010....
- Effect of Intensive Versus Standard Clinic-Based Hypertension Management on Ambulatory Blood Pressure: Results From the SPRINT (Systolic Blood Pressure Intervention Trial) Ambulatory Blood Pressure StudyPaul E Drawz
From the Division of Renal Diseases and Hypertension, University of Minnesota, Minneapolis P E D Department of Biostatistical Sciences, Division of Public Health Sciences, Wake Forest School of Medicine, Winston Salem, NC N M P Michael E DeBakey Veterans Affairs Medical Center and Division of General Internal Medicine, Baylor College of Medicine, Houston, TX J T B Division of Cardiology, Columbia University Medical Center, New York, NY N A B Department of Medicine, Veterans Affairs Medical Center, Memphis, TN W C C Division of Nephrology and Hypertension, Vanderbilt University Medical Center, Nashville, TN J P D Division of Cardiovascular Sciences, National Heart, Lung, and Blood Institute, Bethesda, MD L J F Department of Epidemiology, Colorado School of Public Health, Aurora D C G Nephrology and Hypertension Division, Mayo Clinic, Jacksonville, FL W E H Departments of Medicine and Epidemiology, Ochsner Health System, Tulane University New Orleans, LA M K W Department of Family Medicine, Carolinas HealthCare System, Charlotte, NC A M Division of Nephrology, Veterans Affairs Health System and University of California, San Diego D E R Division of Nephrology, Veterans Affairs Health System and University of Minnesota, Minneapolis Y S Michael E DeBakey Veterans Affairs Medical Center and Division of Hypertension and Clinical Pharmacology, Baylor College of Medicine, Houston,
Hypertension 69:42-50. 2017..Further studies are needed to assess whether targeting hypertension therapy based on ambulatory BP improves clinical outcomes...
- The Antihypertensive and Lipid Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Heart Failure Validation Study: diagnosis and prognosisPaula T Einhorn
National Heart, Lung, and Blood Institute, Division of Epidemiology and Clinical Applications, Bethesda, MD 20892 7936, USA
Am Heart J 153:42-53. 2007..However, questions have been raised regarding the validity of the HF diagnosis...
- Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinoprilJackson T Wright
General Clinical Research Center, Case Western Reserve University, Cleveland, Ohio 44106, USA
JAMA 293:1595-608. 2005..Few cardiovascular outcome data are available for blacks with hypertension treated with angiotensin-converting enzyme (ACE) inhibitors or calcium channel blockers (CCBs)...
- Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood PressureAram V Chobanian
Boston University School of Medicine, Boston, Mass, USA
Hypertension 42:1206-52. 2003..Positive experiences, trust in the clinician, and empathy improve patient motivation and satisfaction. This report serves as a guide, and the committee continues to recognize that the responsible physician's judgment remains paramount...
- Response to six classes of antihypertensive medications by body mass index in a randomized controlled trialBarry J Materson
Cooperative Studies Program of the Department of Veterans Affairs, Office of Research and Development and the Department of Medicine, University of Miami, Miami, FL 33136, USA
J Clin Hypertens (Greenwich) 5:197-201. 2003..01). Only prazosin patients gained weight: 1.7 lb (end-titration, p<0.0001; 1-year, p=0.02). Obesity does not appear to cause resistance to antihypertensive medications...
- The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 reportAram V Chobanian
Department of Medicine, Boston University School of Medicine, Boston, Mass, USA
JAMA 289:2560-72. 2003..Empathy builds trust and is a potent motivator. Finally, in presenting these guidelines, the committee recognizes that the responsible physician's judgment remains paramount...
- The treatment of hypertension in the elderlyMarvin Moser
J Clin Hypertens (Greenwich) 10:58-68. 2008..The authors maintained full control of the discussion and the resulting content of this article...
- The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trialJoel M Neutel
Orange County Research Center, Tustin, CA 92780, USA
J Clin Hypertens (Greenwich) 7:578-86. 2005..Treatments were well tolerated. This irbesartan/HCTZ treatment regimen achieved SBP goals in more than 75% of patients uncontrolled on monotherapy...
- Hypertension and heart failure. Roundtable discussionMarvin Moser
J Clin Hypertens (Greenwich) 6:326-32. 2004
- What should our blood pressure goal be in patients with diabetes?William C Cushman
J Clin Hypertens (Greenwich) 9:823-6. 2007
- Blood pressure control in Hispanics in the antihypertensive and lipid-lowering treatment to prevent heart attack trialKaren L Margolis
HealthPartners Research Foundation PO Box 1524, Mailstop 21111R, Minneapolis, MN 55440 1524, USA
Hypertension 50:854-61. 2007....
- Fosinopril versus amlodipine comparative treatments study: a randomized trial to assess effects on plasminogen activator inhibitor-1Marco Pahor
Sticht Center on Aging, Department of Internal Medicine, Wake Forest University School of Medicine, Winston Salem, NC 27157, USA
Circulation 105:457-61. 2002..ACE inhibitors and calcium antagonists may modulate fibrinolysis. We conducted a randomized controlled trial to assess the effects of these drugs on plasminogen activator inhibitor-1 (PAI-1) antigen, an inhibitor of fibrinolysis...
- Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trialDavid C Goff
Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston Salem, North Carolina 27157 1063, USA
Am J Cardiol 99:4i-20i. 2007..The Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial will test hypotheses to address these unanswered questions...
- Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methodsJohn B Buse
Division of Endocrinology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, NC 27599 7172, USA
Am J Cardiol 99:21i-33i. 2007....
- Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapyElizabeth O Ofili
Clinical Research Center, Morehouse School of Medicine, Atlanta, GA 30310, USA
J Natl Med Assoc 98:618-26. 2006..In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy...
- Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetesJames R Sowers
University of Missouri Columbia and Harry S Truman VA Medical Center, 65212, USA
J Clin Hypertens (Greenwich) 8:470-80. 2006..Irbesartan/HCTZ fixed combinations achieved SBP goals in over half of the T2DM patients and nearly three quarters of patients with the metabolic syndrome, with SBP uncontrolled on antihypertensive monotherapy...
- Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT)William C Cushman
J Clin Hypertens (Greenwich) 4:393-404. 2002..Achievable control rates in varied practice settings and geographic regions and factors that predict improved blood pressure control are not well identified...
- Effects of intensive glucose lowering in type 2 diabetesHertzel C Gerstein
N Engl J Med 358:2545-59. 2008....
- Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood instituteBarry L Carter
Division of Clinical and Administrative Pharmacy, Rm 527, College of Pharmacy, University of Iowa, Iowa City, IA 52242, USA
Hypertension 52:30-6. 2008
- Clinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)Paul K Whelton
Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, New Orleans, LA, USA
Arch Intern Med 165:1401-9. 2005....
- Control of blood pressure: does it matter which agent you use?Marvin Moser
J Clin Hypertens (Greenwich) 9:964-73. 2007..The authors maintained full control of the discussion and the resulting content of this article...
- Hypertension in adults across age groupsDan R Berlowitz
JAMA 294:2970-1; author reply 2971-2. 2005
- Clinical events in high-risk hypertensive patients randomly assigned to calcium channel blocker versus angiotensin-converting enzyme inhibitor in the antihypertensive and lipid-lowering treatment to prevent heart attack trialFrans H H Leenen
University of Ottawa Heart Institute, Ottawa, Ontario, Canada
Hypertension 48:374-84. 2006..Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm...